Improving clozapine utilization will require continued advocacy, drug sponsor interest, and FDA support to address REMS issues

Expert Rev Clin Pharmacol. 2023 Mar;16(3):177-179. doi: 10.1080/17512433.2023.2183192. Epub 2023 Feb 27.

Authors

Jonathan G Leung¹, Megan Ehret², Raymond C Love², Robert O Cotes³

Affiliations

¹ Department of Pharmacy, Mayo Clinic, Rochester.
² Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, MD, USA.
³ Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA.

PMID: 36803289
DOI: 10.1080/17512433.2023.2183192

No abstract available

Publication types

Editorial

MeSH terms

Clozapine*
Humans
Risk Assessment
Risk Management
United States
United States Food and Drug Administration

Substances

Clozapine